BiotechTube

placebo for risankizumab + risankizumab

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis (AS)

Conditions

Ankylosing Spondylitis (AS)

Trial Timeline

Jan 28, 2014 → Jul 25, 2016

NCT ID
NCT02047110

About placebo for risankizumab + risankizumab

placebo for risankizumab + risankizumab is a phase 2 stage product being developed by AbbVie for Ankylosing Spondylitis (AS). The current trial status is completed. This product is registered under clinical trial identifier NCT02047110. Target conditions include Ankylosing Spondylitis (AS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04713592Phase 3Completed
NCT02047110Phase 2Completed

Competing Products

20 competing products in Ankylosing Spondylitis (AS)

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
AdalimumabAbbVieApproved
85
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85